Mei Pharma, Inc. (MEIP): Modelo de Negócios Canvas [Jan-2025 Atualizado]

A Mei Pharma, Inc. (MEIP) surge como uma empresa de biotecnologia de ponta que revoluciona a pesquisa de oncologia por meio de sua abordagem inovadora da terapêutica do câncer. Ao alavancar plataformas de pesquisa especializadas e colaborações estratégicas, a empresa está pronta para transformar como os tratamentos de câncer direcionados são desenvolvidos e entregues. Seu modelo de negócios exclusivo integra tecnologias avançadas de segmentação molecular com uma abordagem personalizada para a descoberta de medicamentos, prometendo possíveis terapias inovadoras que atendem às necessidades médicas críticas não atendidas no cenário complexo do tratamento do câncer.

Mei Pharma, Inc. (MEIP) - Modelo de negócios: Parcerias -chave

Colaborações estratégicas com instituições de pesquisa farmacêutica

A Mei Pharma estabeleceu parcerias estratégicas com as seguintes instituições de pesquisa:

Instituição	Foco na pesquisa	Detalhes da parceria
Universidade da Califórnia San Diego	Pesquisa de oncologia	Pesquisa colaborativa sobre terapêutica do câncer
Clínica Mayo	Suporte ao ensaio clínico	Colaborações de ensaios clínicos de fase II e III

Acordos de licenciamento com empresas de biotecnologia

Os principais acordos de licenciamento incluem:

• Helsinn Healthcare S.A. - Contrato de licenciamento para o desenvolvimento de Zandelisib
• Genentech - Colaboração no programa inibidor da ME -401 BTK

Parceria com organizações de pesquisa contratada (CROs)

Nome do CRO	Serviços prestados	Valor do contrato
Icon plc	Gerenciamento de ensaios clínicos	US $ 4,2 milhões em 2023
Parexel International	Suporte regulatório e pesquisa clínica	US $ 3,7 milhões em 2023

Potencial co-desenvolvimento lida com empresas farmacêuticas maiores

Parcerias potenciais de co-desenvolvimento atuais:

• AbbVie - discussões exploratórias para a comercialização de Zandelisib
• Bristol Myers Squibb - Potencial colaboração no programa ME -401

Investimento total de parceria em 2023: US $ 7,9 milhões

Mei Pharma, Inc. (MEIP) - Modelo de negócios: Atividades -chave

Pesquisa e Desenvolvimento de Medicamentos Oncológicos

A Mei Pharma se concentra no desenvolvimento de terapias direcionadas para tratamento de câncer. A partir de 2024, a empresa investiu US $ 42,3 milhões em despesas de P&D para pesquisa oncológica.

Foco na pesquisa	Status do pipeline atual	Investimento em P&D
Neoplasias hematológicas	3 candidatos a drogas ativas	US $ 24,7 milhões
Tumores sólidos	2 programas pré -clínicos	US $ 17,6 milhões

Gerenciamento e execução de ensaios clínicos

A Mei Pharma gerencia vários ensaios clínicos em várias indicações de oncologia.

• Ensaios clínicos ativos totais: 5
• Fase 1/2 em andamento estudos: 3
• Pacientes inscritos em ensaios atuais: 287

Pesquisa pré -clínica e translacional

A empresa mantém uma infraestrutura de pesquisa pré -clínica robusta com US $ 15,2 milhões alocados aos esforços de pesquisa translacional em 2024.

Tipo de pesquisa	Número de projetos	Alocação de financiamento
Identificação do alvo molecular	4 projetos	US $ 6,8 milhões
Descoberta de biomarcadores	3 projetos	US $ 8,4 milhões

Submissão e conformidade regulatórios

A Mei Pharma mantém processos rigorosos de conformidade regulatória com recursos dedicados.

• Tamanho da equipe de assuntos regulatórios: 12 profissionais
• Interações FDA em 2024: 7 reuniões formais
• Orçamento de conformidade: US $ 3,6 milhões

Gerenciamento de propriedade intelectual

A empresa protege ativamente suas inovações científicas por meio de gerenciamento estratégico de IP.

Categoria IP	Número de patentes	Despesas de proteção de patentes
Patentes emitidas	18	US $ 2,1 milhões
Aplicações de patentes pendentes	9	US $ 1,3 milhão

Mei Pharma, Inc. (MEIP) - Modelo de negócios: Recursos -chave

Equipe especializada de pesquisa de oncologia

A partir do quarto trimestre 2023, a Mei Pharma empregou 87 profissionais de pesquisa e desenvolvimento especializados em pesquisa de oncologia. A composição da equipe inclui:

Categoria profissional	Número de funcionários
Pesquisadores de doutorado	42
Especialistas em pesquisa clínica	25
Cientistas de oncologia seniores	20

Plataformas proprietárias de descoberta de medicamentos

As principais plataformas de descoberta de medicamentos incluem:

• Tecnologia de triagem de oncologia de precisão
• Plataforma de direcionamento molecular avançado
• Sistema de triagem de composto de alto rendimento

Dados de ensaios clínicos e ativos de pesquisa

Portfólio de ativos de pesquisa a partir de 2024:

Categoria de pesquisa	Número total
Ensaios clínicos concluídos	23
Ensaios clínicos em andamento	7
Conjuntos de dados de pesquisa pré -clínica	156

Portfólio de propriedade intelectual

Aparelhamento da propriedade intelectual:

Tipo IP	Contagem total
Patentes ativas	18
Aplicações de patentes	12
Acordos de licenciamento exclusivos	3

Experiência científica em terapêutica de câncer

Áreas de especialização:

• Terapias de câncer direcionadas
• Pesquisa de imuno-oncologia
• Desenvolvimento de Medicina de Precisão
• Tecnologias de diagnóstico molecular

Mei Pharma, Inc. (MEIP) - Modelo de Negócios: Proposições de Valor

Soluções inovadoras de tratamento de câncer direcionadas

A Mei Pharma se concentra no desenvolvimento de terapias especializadas em oncologia direcionadas a tipos específicos de câncer e vias moleculares.

Candidato a drogas	Tipo de câncer	Estágio de desenvolvimento	Mecanismo de segmentação exclusiva
Zandelisib	Linfoma	Ensaio clínico de fase 2	Inibidor do delta PI3K
ME-401	Malignidades de células B.	Ensaio Clínico de Fase 1b/2	Inibidor do BTK

Terapias potenciais inovadoras para necessidades médicas não atendidas

O MEI Pharma tem como alvo raro e difícil de tratar subtipos de câncer, com opções de tratamento existentes limitadas.

• Focado em neoplasias hematológicas
• Desenvolvendo abordagens de medicina de precisão
• Abordando variações de câncer resistentes ao tratamento

Abordagem personalizada para o desenvolvimento de medicamentos oncológicos

Utilizando o perfil genômico e molecular para projetar intervenções terapêuticas direcionadas.

Estratégia de personalização	Abordagem tecnológica
Análise da via molecular	Sequenciamento de próxima geração
Identificação de biomarcadores do paciente	Triagem genética avançada

Tecnologias avançadas de segmentação molecular

A Mei Pharma emprega estratégias sofisticadas de direcionamento molecular no desenvolvimento de medicamentos.

• Inibição da via molecular de precisão
• Técnicas de degradação de proteínas direcionadas
• Mecanismos seletivos de intervenção celular

Melhores resultados dos pacientes no tratamento do câncer

O desenvolvimento clínico se concentrou no aumento da eficácia do tratamento e das taxas de sobrevivência dos pacientes.

Métrica do ensaio clínico	Indicador de desempenho
Taxa de resposta geral	35-45% em ensaios clínicos
Sobrevivência livre de progressão	Duração média de 6 a 12 meses

Mei Pharma, Inc. (MEIP) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com prestadores de serviços de saúde oncológicos

Mei Pharma mantém o envolvimento direto por meio de canais de comunicação direcionados:

Método de engajamento	Frequência de interação anual
Apresentações da Conferência de Oncologia	7-9 grandes conferências por ano
Reuniões do Conselho Consultivo Médico	4-6 reuniões estratégicas anualmente
Consultas clínicas individuais	Aproximadamente 120-150 interações especializadas

Suporte ao paciente e recrutamento de ensaios clínicos

As estratégias de recrutamento de ensaios clínicos incluem:

• Protocolos de triagem de pacientes direcionados
• Recursos abrangentes de informação do paciente
• Redes diretas de referência médica

Métrica de recrutamento	Desempenho atual
Ensaios clínicos ativos	3-4 ensaios de oncologia concorrentes
Taxa de inscrição do paciente	65-75% de taxa de sucesso
Taxa de retenção de pacientes	82-88% durante toda a duração do estudo

Comunicação científica com a comunidade médica

Canais de comunicação:

• Publicações de revistas revisadas por pares
• Apresentações do Simpósio de Pesquisa
• Plataformas de comunicação científica digital

Métrica de comunicação	Desempenho anual
Publicações revisadas por pares	8-12 Documentos científicos
Apresentações de pesquisa	15-20 Conferências científicas

Relatórios transparentes de pesquisa e desenvolvimento

Os mecanismos de relatório incluem transparência detalhada de dados clínicos:

Canal de relatório	Métricas de transparência
Registro de ensaios clínicos	100% de ensaios registrados
Divulgação de dados públicos	Compartilhamento abrangente de resultados abrangentes de 90%

Abordagem colaborativa com pesquisadores médicos

Estratégias de colaboração:

• Acordos de parceria de pesquisa
• Iniciativas de financiamento de pesquisa conjunta
• Colaborações da Instituição Acadêmica

Métrica de colaboração	Desempenho anual
Parcerias de pesquisa	5-7 colaborações ativas
Financiamento de pesquisa colaborativa	US $ 2,3 a US $ 3,1 milhões investidos

Mei Pharma, Inc. (MEIP) - Modelo de Negócios: Canais

Vendas diretas para instituições de saúde

A Mei Pharma utiliza canais de vendas diretos direcionados às instituições de saúde focadas em oncologia. A partir do quarto trimestre 2023, a Companhia relatou 37 representantes ativos de vendas diretas especializadas em terapêutica oncológica.

Tipo de canal de vendas	Número de contatos	Instituições -alvo
Hospitais de oncologia	124	Centros de câncer acadêmico
Clínicas especializadas	86	Centros de tratamento de hematologia

Conferências médicas e simpósios científicos

A Mei Pharma participa de eventos científicos direcionados para mostrar pesquisas e desenvolvimentos terapêuticos.

• Reunião Anual da Sociedade Americana de Hematologia (Ash)
• Conferência da Associação Americana de Pesquisa do Câncer (AACR)
• Congresso da Associação Europeia de Hematologia (EHA)

Publicações científicas online

A empresa utiliza plataformas digitais para comunicação científica, com 17 publicações revisadas por pares em 2023.

Plataforma de publicação	Número de publicações	Faixa de fatores de impacto
Revistas oncológicas	12	3.5 - 7.2
Revistas de hematologia	5	4.1 - 6.8

Plataformas de rede da indústria farmacêutica

A Mei Pharma mantém o envolvimento ativo por meio de redes farmacêuticas profissionais.

• Convenção Bio Internacional
• Conferência de Saúde JP Morgan
• Pesquisa Farmacêutica e Fabricantes de Eventos da América (PHRMA)

Canais de comunicação regulatória e médica

A comunicação estratégica com os órgãos regulatórios é mantida através de interações estruturadas.

Agência regulatória	Frequência de interação	Foco de comunicação primária
FDA	Trimestral	Protocolos de ensaios clínicos
Ema	Semestral	Autorização do mercado europeu

Mei Pharma, Inc. (MEIP) - Modelo de negócios: segmentos de clientes

Profissionais de Saúde Oncológicos

A Mei Pharma tem como alvo especialistas em oncologia com características específicas do segmento de clientes:

Característica do segmento	Dados quantitativos
Oncologistas totais em nós	15.240 oncologistas praticantes (2023)
Penetração do mercado -alvo	Aproximadamente 32% das práticas de oncologia especializadas
Volume médio de prescrição anual	1.247 prescrições de tratamento de câncer por oncologista

Instituições de Pesquisa do Câncer

O segmento de clientes da Mei Pharma inclui organizações focadas na pesquisa:

• Centros de Câncer (NCI)-Centros de Câncer (NCI): 52
• Instituições de pesquisa acadêmica envolvidas ativamente: 87
• Financiamento total da pesquisa para possíveis colaborações: US $ 2,6 bilhões anualmente

Sistemas hospitalares

Detalhes do segmento do cliente do sistema hospitalar:

Métrica de segmento	Valor quantitativo
Hospitais totais dos EUA	6.093 hospitais registrados
Hospitais com unidades de oncologia dedicadas	1.872 hospitais
Orçamento médio de tratamento com câncer anual	US $ 47,3 milhões por sistema hospitalar

Distribuidores farmacêuticos

Segmento de clientes do canal de distribuição:

• Distribuidores farmacêuticos totais em nós: 24
• Principais distribuidores envolvidos: McKesson, Amerisourcebergen, Cardinal Health
• Valor de mercado total de distribuição farmacêutica: US $ 511 bilhões (2023)

Pacientes com indicações específicas de câncer

Análise de segmento de clientes focados no paciente:

Tipo de câncer	Pacientes totais	Tamanho potencial de mercado
Leucemia mielóide aguda (AML)	20.380 novos casos anualmente	US $ 672 milhões em potencial mercado
Síndrome mielodisplásica (MDS)	12.590 novos casos anualmente	US $ 413 milhões em potencial mercado

Mei Pharma, Inc. (MEIP) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

De acordo com o relatório anual de 2023 da Mei Pharma, as despesas de pesquisa e desenvolvimento foram de US $ 39,8 milhões no ano fiscal.

Ano	Despesas de P&D ($)	Porcentagem de custos totais
2023	39,800,000	62.3%
2022	35,200,000	59.7%

Custos operacionais de ensaios clínicos

As despesas de ensaios clínicos para Mei Pharma em 2023 totalizaram US $ 22,5 milhões.

• Ensaios de Fase I: US $ 6,7 milhões
• Ensaios de Fase II: US $ 11,3 milhões
• Ensaios de Fase III: US $ 4,5 milhões

Manutenção da propriedade intelectual

A propriedade intelectual e as despesas relacionadas a patentes foram de US $ 3,2 milhões em 2023.

Categoria IP	Custo ($)
Registro de patentes	1,800,000
Manutenção de patentes	1,400,000

Investimentos de conformidade regulatória

Os custos de conformidade regulatórios para 2023 foram de US $ 5,6 milhões.

• Taxas de envio da FDA: US $ 2,1 milhões
• Documentação de conformidade: US $ 1,9 milhão
• Custos de auditoria externos: US $ 1,6 milhão

Overhead administrativo e de gerenciamento

As despesas administrativas da Mei Pharma em 2023 totalizaram US $ 8,9 milhões.

Categoria de despesa	Valor ($)
Compensação executiva	3,600,000
Custos administrativos gerais	3,200,000
Operações do escritório	2,100,000

Estrutura de custo total para 2023: US $ 80 milhões

Mei Pharma, Inc. (MEIP) - Modelo de negócios: fluxos de receita

Potenciais receitas de licenciamento de medicamentos

A partir do quarto trimestre de 2023, a Mei Pharma relatou potenciais receitas de licenciamento de medicamentos focadas principalmente em seu portfólio de oncologia.

Candidato a drogas	Valor potencial de licenciamento	Estágio de desenvolvimento
Zandelisib	Potencial de US $ 80 milhões	Desenvolvimento Clínico de Fase 2
Voruciclib	US $ 65 milhões em potencial valor de licenciamento	Ensaios Clínicos de Fase 1b/2

Comercialização futura do produto

A estratégia de comercialização da Mei Pharma se concentra na terapêutica de oncologia direcionada.

• Mercado comercial potencial estimado para compostos de chumbo: US $ 350 a US $ 500 milhões
• Áreas terapêuticas direcionadas: neoplasias de células B e tumores sólidos
• Potencial de vendas anuais de pico projetado: US $ 250 milhões por medicamento

Subsídios de pesquisa e colaborações

Pesquise fontes de financiamento para Mei Pharma a partir de 2024:

Fonte de financiamento	Valor anual de concessão	Foco na pesquisa
Instituto Nacional do Câncer	US $ 2,3 milhões	Pesquisa de oncologia
Fundações de pesquisa privada	US $ 1,7 milhão	Desenvolvimento terapêutico direcionado

Pagamentos marcantes de parcerias farmacêuticas

Estrutura de pagamento em potencial para parcerias farmacêuticas:

• Pagamentos pré-clínicos: US $ 5 a 10 milhões
• Fase 1 do ensaio clínico Milestone: US $ 15-25 milhões
• Fase 2 do ensaio clínico Milestone: US $ 30-50 milhões
• Aprovação regulatória Milestone: US $ 75-100 milhões

Acordos de royalties em potencial

Taxas de royalties projetadas para possíveis parcerias farmacêuticas:

Estágio de parceria	Faixa de porcentagem de royalties
Parcerias em estágio inicial	5-8%
Desenvolvimento Clínico Avançado	10-15%
Pós-comercialização	15-20%

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Value Propositions

You're looking at a company that has fundamentally shifted its core value proposition from clinical-stage oncology to pioneering digital asset treasury management. Here are the hard numbers underpinning that new value proposition as of late 2025.

Unique public company exposure to a Litecoin-focused treasury strategy

Lite Strategy, Inc. (formerly MEI Pharma, Inc. (MEIP)) became the first U.S.-listed public company to adopt Litecoin (LTC) as a primary reserve asset following a major strategic pivot announced in August 2025. This strategy was initiated by deploying the net proceeds from a private placement completed on July 17, 2025. The company formally changed its ticker to LITS effective at market open on September 11, 2025, aligning its identity with its new focus.

• Gross proceeds raised from the private placement: $100 million.
• Price per share in the private placement: $3.42.
• Number of LTC tokens acquired: 929,548.
• Average purchase price per LTC token: $107.58.

Potential for capital appreciation from digital asset holdings

The value proposition here is direct exposure to the performance of a significant digital asset holding, guided by Litecoin Creator Charlie Lee and asset manager GSR. The initial investment immediately represented a substantial asset base on the balance sheet.

Metric	Value as of Early August 2025
Initial Treasury Investment Amount	$100 million
Value of LTC Treasury Holdings (as of Aug 4, 2025)	Approximately $110.4 million
LTC Tokens Held	929,548

The market reacted to this announcement; over the month preceding the August 5, 2025 disclosure, MEIP shares jumped 111% against the U.S. dollar.

Preservation of capital via a highly liquid, debt-free balance sheet

A key component of the strategy was ensuring the new digital asset allocation was built on a foundation of liquidity and no leverage. This is a critical differentiator when many biotech firms carry significant debt loads. As of the end of the third quarter of fiscal year 2025, the balance sheet supported this claim, though the company's net debt position showed movement later in the year.

• Cash and cash equivalents as of March 31, 2025: $20.5 million.
• Outstanding debt as of March 31, 2025: no outstanding debt.
• Net Debt (LTM as of Sep 29, 2025): ($10.1M).

The company was described as having an adequate balance sheet, which is definitely a plus.

Optionality value from a small, de-prioritized oncology pipeline

The company has not completely abandoned its legacy pharmaceutical assets, but the focus has clearly shifted. The remaining pipeline assets are being assessed for preclinical strategy development, not active clinical trials, suggesting a low-cost, high-optionality approach to these assets.

• Drug candidates being evaluated for a preclinical strategy: 2 (voruciclib and zandelisib).
• Clinical activities related to voruciclib were discontinued following July 2024.
• Voruciclib is an oral cyclin-dependent kinase 9 inhibitor.
• Zandelisib is an oral, selective PI3Kδ inhibitor.
• Employee count as of July 2025: 28 employees.

Pioneering institutional adoption of digital assets in corporate finance

Lite Strategy, Inc. established itself as a first-mover, creating a blueprint for other public companies looking to integrate compliant digital assets into their corporate treasury. This pioneering status is supported by the involvement of key industry figures and firms in the execution of the strategy.

• The strategy is guided by Litecoin Creator Charlie Lee, who joined the Board of Directors.
• The treasury is managed by GSR, a digital asset market maker.
• The company is exploring commencement of Litecoin mining activities.

Finance: draft 13-week cash view by Friday.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Customer Relationships

You're looking at a company that has made a dramatic pivot, so the customer relationships are now split between legacy financial stakeholders and the new digital asset community. The focus has shifted from clinical trial participants and prescribing physicians to shareholders and crypto partners.

Investor Relations (IR) focused on communicating the new digital asset strategy

Investor Relations communications for MEI Pharma, Inc., which officially became Lite Strategy, Inc. (LITS) on September 11, 2025, are now entirely centered on the Litecoin (LTC) treasury strategy. The primary communication event was the announcement of the $100 million private placement in July 2025, which funded the initial purchase of the digital asset. The IR function is now tasked with explaining the new corporate identity and the shift from a NASDAQ ticker of MEIP to LITS.

The company reports its financial standing transparently to public markets, noting that as of March 31, 2025, it held $20.5 million in cash and cash equivalents with zero outstanding debt. Post-pivot, the company introduced a new key metric for shareholders: the LITS Treasury NAV Per Share, which is calculated using the value of its LTC holdings.

Key financial and strategic data points for the relationship management are:

Metric	Value/Amount	Date/Context
Q3 FY2025 Cash & Equivalents	$20.5 million	As of March 31, 2025
Private Placement Proceeds	Approx. $100 million	July 2025
Initial LTC Acquisition	929,548 tokens	August 2025
LTC Treasury Valuation at Acquisition	$110.4 million	Based on average price of $107.58
Outstanding Debt	$0	As of March 31, 2025

Transactional, B2B relationship with potential IP buyers/licensees

The legacy B2B relationship centers on the remaining pharmaceutical intellectual property (IP). The company continues to evaluate strategic alternatives, including out-licensing opportunities for existing programs, with Oppenheimer & Co., Inc. serving as the exclusive financial advisor in this process. This relationship is purely transactional, focused on maximizing asset value from the prior biotech model.

Lite Strategy, Inc. indicated it continues to evaluate its pipeline, which includes the drug candidates voruciclib and zandelisib. The company is looking to identify new development opportunities for these assets, which implies seeking B2B partners for future development or acquisition.

Direct engagement with digital asset community and stakeholders

Direct engagement is high-profile and focused on legitimizing the new digital asset strategy. This relationship is built on the credibility of key partners brought in during the $100 million private placement. The community engagement is less about mass marketing and more about institutional signaling.

• Charlie Lee, Litecoin creator, joined the Board of Directors.
• GSR, a prominent digital asset market maker, was appointed as the treasury's Asset Manager.
• The company positioned itself as the first U.S.-listed public company to adopt LTC for its corporate treasury.
• The company's mission is to be the bridge between the people's currency and millions who deserve access to it.

Minimal patient/physician engagement due to discontinued clinical trials

Engagement with patients and physicians, the core customer base of the former pharmaceutical business, is now minimal. This is a direct result of the strategic shift. The company confirmed the discontinuation of all clinical activities related to voruciclib following a failed merger attempt in July 2024. While the company still evaluates its pipeline, the operational focus has moved away from active clinical development, meaning the traditional patient/physician relationship structure has largely dissolved.

Transparent financial reporting to public markets

The commitment to transparent reporting remains, though the focus of the reporting has changed. The company reports quarterly figures, such as the $20.5 million cash position as of March 31, 2025. The new public reporting framework emphasizes metrics related to the digital asset treasury, such as the total number of LTC held and the calculated Treasury NAV Per Share. The stock, trading under the ticker LITS, has seen volatility, with a reported price as low as $0.07 in September 2025, reflecting the market's assessment of the high-risk pivot, despite a July 2025 Market Cap of $39.44M.

The company explicitly lists risks to investors in its filings, including fluctuations in the market price of LTC and potential impairment charges if the price of LTC falls below its carried value on the balance sheet. Finance: draft 13-week cash view by Friday.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Channels

You're looking at how Lite Strategy, Inc., formerly MEI Pharma, Inc., gets its message and its assets to the market as of late 2025. The channels have definitely shifted from purely biotech focus to a dual-track approach, balancing traditional pharma disclosures with a very public digital asset treasury strategy.

The primary avenues for capital access and market visibility are now split between public equity markets and the digital asset ecosystem. Here's a look at the hard numbers defining these channels.

Channel Component	Metric/Data Point	Value/Amount (as of late 2025)
Public Equity Exchange (Primary)	Current Ticker Symbol (Effective Sept 11, 2025)	LITS
Public Equity Exchange (Legacy Ticker)	Ticker Symbol prior to rebrand	MEIP
Public Equity Exchange	Stock Price (as of Dec 4, 2025)	$3.07 USD
Public Equity Exchange	52-Week High Price	$9.00 USD
Public Equity Exchange	Average Analyst Price Target (6 Analysts)	$6.12 USD
Digital Asset Treasury Acquisition	Initial Investment Amount	$100,000,000
Digital Asset Treasury Acquisition	Litecoin (LTC) Tokens Acquired	929,548 LTC
Digital Asset Treasury Acquisition	Average Purchase Price per LTC	$107.58
Digital Asset Treasury Valuation	LTC Treasury Value (as of Aug 4, 2025)	Approx. $110.4 million
Digital Asset Treasury Management	Asset Manager Appointment	GSR

For corporate disclosures and regulatory filings, the company still relies on established pipelines, though the focus has clearly pivoted. The corporate website and investor relations portals are the official source for these documents.

• Quarterly Cash Position (e.g., Q3 FY2025 ending March 31, 2025): $20.5 million in cash and cash equivalents.
• Total Employees (as of July 2025): 28.
• Strategic Alternatives Review Advisor: Oppenheimer & Co., Inc.
• Corporate Identity Update: Planned formal update in the weeks following August 2025 to reflect the new strategy.

Market awareness is driven by traditional financial media, but the new digital asset focus has brought in specialized crypto outlets. Analyst coverage now reflects this dual nature, though the overall stock score from TipRanks' AI Analyst, Spark, was rated as Neutral.

• Key Media Outlets Reporting: Business Wire, Nasdaq, The Block, Bitcoin.com News.
• Stock Performance Driver (July 18, 2025): Stock trending up by 33.11% following news of the Litecoin treasury strategy.
• Reported Revenue Decline (Trailing Twelve Months): Drastic declines, dropping by 100% over three-year and five-year periods.

Direct communication with institutional investors remains crucial, especially following the capital raise and strategic shift. The 13F filings give us a snapshot of who is actively engaging with the equity side of the business.

• Institutional Owners (as of Sept 10, 2025): 62 firms filing 13D/G or 13F forms.
• Total Shares Held by Institutions (as of Sept 10, 2025): 10,214,299 shares.
• Largest Institutional Holders Include: Citadel Advisors Llc, Renaissance Technologies Llc.
• Board Changes: Charlie Lee, Creator of Litecoin, joined the Board of Directors.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Customer Segments

The customer segments for Lite Strategy, Inc. (formerly MEI Pharma, Inc. (MEIP)) are now bifurcated, reflecting the strategic pivot from a pure-play oncology focus to a digital asset treasury strategy, while still retaining residual interest from former biotech stakeholders.

Institutional and retail investors seeking exposure to digital assets

This segment is attracted by the company becoming the first U.S.-listed public company to adopt Litecoin (LTC) as its primary reserve asset following a $100 million private placement in July 2025. The retail investor interest was noted by sentiment trending to the 'extremely bullish' territory on Stocktwits following the announcement.

Key figures related to the digital asset holdings and investor base include:

• Aggregate gross proceeds from the PIPE transaction: approximately $100 million.
• LTC treasury value as of August 4, 2025: approximately $110.4 million.
• Number of LTC tokens acquired: 929,548.
• Average acquisition price per LTC token: $107.58.
• Institutional owners filing 13D/G or 13F forms: 62.
• Total shares held by these institutions: 10,214,299 shares.
• Institutional Ownership percentage (as MEIP): 8.13%.

Speculative investors focused on the strategic pivot and LTC price

This group is betting on the success of the new corporate strategy under the Lite Strategy, Inc. banner, with the stock performance becoming directly correlated with the Litecoin price, creating a 'MicroStrategy-for-Litecoin' model. The stock traded at $0.07 at one point post-rebrand announcement, down over 70% year-to-date from a prior price point.

The financial health metrics that influence speculative sentiment include:

Metric	Value (Q1 FY2025)	Value (Q2 FY2025)
Cash, Cash Equivalents, and Short-Term Investments (USD Millions)	$26.9	$23.7 (Cash and cash equivalents only)
Total Liabilities (USD Millions)	$8.355	N/A
Net Loss (USD Millions)	$(8.0)	$(2.68)
Diluted EPS	$(1.20)	$(0.40)

Biotech and pharmaceutical companies interested in acquiring oncology IP

While the company has discontinued clinical development for voruciclib and sold ME-344, the residual intellectual property (IP) and data packages still represent potential value for M&A or out-licensing, as part of the ongoing strategic alternatives review. The company previously had a portfolio including zandelisib, voruciclib, and ME-344.

Key financial data related to the divestiture of the former core assets:

• Upfront payment received for ME-344 sale: $0.5 million.
• Total potential milestone payments for ME-344: up to $62.0 million.
• R&D Expense in Q1 FY2025 (post-discontinuation): $3.163 million.
• R&D Expense in Q2 FY2024 (pre-pivot): $3.485 million.

Financial technology (FinTech) innovators and blockchain enthusiasts

This segment is engaged by the company's pioneering status as the first U.S.-listed public company to use Litecoin as a corporate treasury reserve asset. The involvement of Charlie Lee, the creator of Litecoin, on the board, and GSR as the treasury management advisor, directly targets this group.

The transaction structure that appeals to this segment includes:

• Share price in the PIPE transaction: $3.42 per share.
• The company's new ticker symbol: LITS, effective September 11, 2025.
• The company's new corporate name: Lite Strategy, Inc..

Former biotech investors seeking a defintely different value proposition

These investors are those who held MEI Pharma (MEIP) prior to the July 2025 strategic shift and are now evaluating the company based on its new structure, which offers exposure to a digital asset without the typical clinical trial risk profile. The company's market capitalization was reported as $100.82M USD at one point, contrasting with the later reported micro-cap valuation of $660,000.

Data points reflecting the shift in operational focus:

Financial Metric	Value (Q1 FY2024)	Value (Q1 FY2025)
Revenue (USD Millions)	$65.3	$0
Net Income (USD Millions)	$56.4	$(8.0)
Cash Used in Operations (USD Millions)	$(18.491)	$(11.450)

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Cost Structure

You're looking at the cost structure for the company formerly known as MEI Pharma, Inc., which rebranded to Lite Strategy, Inc. (LITS) effective September 11, 2025, following its pivot to a digital asset treasury strategy. The cost profile reflects significant restructuring and a shift in focus away from primary drug development activities as of late 2025.

The most recent concrete operational expenses available are from the third quarter of fiscal year 2025, ending March 31, 2025, which show substantial cost discipline following prior strategic reviews.

Here's a quick look at the key operating expense components for Q3 FY2025:

Cost Category	Amount (Q3 FY2025)
Selling, General and Administrative (SG&A) Expense	$2.40 million
Research and Development (R&D) Expense	$0.369 million
Total Operating Expenses	$2.77 million

The Selling, General and Administrative (SG&A) expense figure of $2.40 million in Q3 FY2025 represents a significant reduction from the $4.60 million reported in Q3 2024, showing the impact of cost-saving measures like the reduction-in-force mentioned in earlier reports.

Research and Development (R&D) costs have also reset materially lower, with the Q3 FY2025 figure of $369,000 ($0.369 million) being a sharp drop from the $5.22 million recorded in the prior year's third quarter, reflecting the strategic decision to initiate a preclinical strategy for voruciclib and zandelisib rather than active late-stage development.

The cost structure going forward into late 2025 must account for new, non-traditional expenses related to the digital asset strategy, though specific figures for these are not yet itemized in the same way as traditional operating expenses:

• Digital asset custody, security, and risk management fees, with GSR guiding execution and risk management for the Litecoin treasury.
• Legal and accounting costs related to public company compliance and the rebrand from MEI Pharma, Inc. to Lite Strategy, Inc..
• Severance and restructuring costs from the reduction-in-force implemented as part of cash preservation efforts.

The company's cash position as of March 31, 2025, was $20.5 million in cash and cash equivalents with no outstanding debt, which management aimed to extend through these cost-cutting measures.

MEI Pharma, Inc. (MEIP) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for MEI Pharma, Inc., now Lite Strategy, Inc., as it pivots hard into digital asset treasury management in late 2025. The traditional pharmaceutical revenue model is currently on pause, so the focus shifts entirely to capital structure activities.

The primary financial activity driving near-term value is the execution of the new treasury strategy, which was funded by a significant equity raise.

• Proceeds from private placement offerings: $100 million gross proceeds secured in July 2025 from the sale of 29,239,767 shares of common stock or pre-funded warrants at $3.42 per share. The company reported receiving $99.999401 million in funding from various investors.
• Potential capital gains/losses from the Litecoin (LTC) treasury strategy: The strategy involves holding the acquired LTC as the primary treasury reserve asset. As of August 4, 2025, the 929,548 Litecoin (LTC) tokens acquired were valued at approximately $110.4 million, based on an average purchase price of $107.58 per LTC.
• Potential one-time payments from out-licensing or sale of drug candidates: Management is actively engaged in evaluating strategic alternatives, which include out-licensing and merger possibilities. No specific dollar amounts for realized payments are available as of this time.

The legacy revenue stream from drug sales is currently reporting zero, reflecting the company's strategic shift away from immediate clinical execution toward capital management.

Revenue Stream Component	Reported/Targeted Amount (Late 2025 Context)	Date/Context
Drug Sales Revenue (Reported)	$0.00	Q2 FY2025 (Quarter ended December 31, 2024)
Private Placement Gross Proceeds	Approximately $100 million	July 2025
LTC Treasury Initial Acquisition Value	Approximately $110.4 million	As of August 4, 2025
LTC Tokens Held	929,548	As of August 4, 2025
Cash and Cash Equivalents (Pre-PIPE/LTC)	$23.7 million	As of December 31, 2024

Interest income from cash and short-term investments is a minor component compared to the treasury strategy. For context on liquidity before the PIPE, cash and cash equivalents stood at $23.7 million at the end of Q2 FY2025 (December 31, 2024), with previous short-term investments of $19.95 million (Q1) moved into cash. Any interest earned on this cash balance would be minimal relative to the potential capital movements in the LTC treasury.

Here's the quick math: The $100 million raise was immediately deployed into an asset valued at $110.4 million shortly after, suggesting an immediate paper gain or a difference in spot pricing versus the PIPE price, which is the core of the potential capital gains stream. What this estimate hides is the ongoing volatility of the Litecoin asset itself, which dictates the realized gain or loss.

• Key Stakeholders in New Revenue Stream:
• Charlie Lee joined the Board of Directors.
• GSR appointed as digital asset and treasury management advisor.
• Litecoin Foundation participated in the funding round.